Sign In
Search Icon
Menu Icon

Module 5: Additional Resources

Federal Response to COVID-19: Therapeutics Clinical Implementation Guide (Outpatient Administration Guide for Healthcare Providers)

COVID-19 Vaccination after mAb Administration

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the US 

  • Non-hospitalized COVID-19 patients who previously received passive antibody therapy
  • There is no longer any need to delay vaccination following receipt of monoclonal antibody or convalescent plasma beyond recovery from the acute illness (if symptoms were present) and criteria to discontinue isolation have been met. 
  • Hospitalized COVID-19 patients 

Reporting Cadence

For sotrovimab,
 bam/ete, REGEN-COV,
bebtelovimab, Evusheld

HPOP icon  

Reporting required
once a month by 11:59ET pm the last day of the month

and Lagevrio

HPOP icon

Reporting required at least twice a month by 11:59ET pm on the 15th and last day of the month

Sites with inventory of USG-purchased COVID-19 therapeutics must provide information on product utilization, wastage and stock on hand

COVID-19 Therapeutic Resources

CIG Right-Nav